Reduction of Insulin Requirement After Starting Treatment With Sacubitril/Valsartan in a Patient with Diabetes Treated With Continuous Subcutaneous Insulin Infusion (CSII): A case report-Reference-Cited by-同舟云学术

Reduction of Insulin Requirement After Starting Treatment With Sacubitril/Valsartan in a Patient with Diabetes Treated With Continuous Subcutaneous Insulin Infusion (CSII): A case report

Published:2018-07-11 Issue:6 Volume:12 Page:1254-1255
ISSN:1932-2968
Container-title:Journal of Diabetes Science and Technology
language:en
Short-container-title:J Diabetes Sci Technol

Author:

Gamarra Elena¹,Baffoni Claudia¹,Borretta Giorgio¹,Feola Mauro²,Tassone Francesco¹

Affiliation:

1. Division of Endocrinology, Diabetes & Metabolism, Santa Croce e Carle Hospital, Cuneo, Italy

2. Division of Cardiology, Regina Montis Regalis Hospital, Mondovi, Italy

Publisher

SAGE Publications

Subject

Biomedical Engineering,Bioengineering,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1932296818785644

Reference3 articles.

1. Role of diabetes in congestive heart failure: The Framingham study

2. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

3. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Angiotensin receptor blocker-neprilysin inhibitor for heart failure with reduced ejection fraction;Pharmacological Research;2024-06

2. Effects of Sacubitril/Valsartan on Glycemic Control in Japanese Patients With Heart Failure and/or Hypertension;Circulation Reports;2022-12-09

3. The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus;ESC Heart Failure;2022-12-07

4. Resolution of Hypoglycemia Following Cessation of Sacubitril–Valsartan Combination Therapy in a Nondiabetic Patient;CJC Open;2022-12

5. Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control;International Journal of Cardiology;2022-11